Skip to content
Screener

Opus Genetics IRD Stock Issued During Period Value Registered Direct Offering

Stock Issued During Period Value Registered Direct Offering at other companies

TMC the metals company Inc. logo
TMC the metals company Inc.TMC
$6.97M
CTO
Citius Oncology, Inc.CTOR
$1.89M
CTO
Citius Oncology, Inc.CTOR
$1.9M
Lightbridge logo
LightbridgeLTBR
$25.8M-39.9%
Evommune logo
EvommuneEVMN
$577.47K
Norwood Financial logo
Norwood FinancialNWFL
$50K+85.2%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$304.5M+381%
Enterprise value$245.74M+672%
P/S25.4×+21.3×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:StockIssuedDuringPeriodValueRegisteredDirectOffering.

The source filing: Opus Genetics’s 10-K, filed March 12, 2026.

Filed
Mar 11, 2026, 8:00 PM EDT
Fiscal year
FY2025
Accession
0001140361-26-009247
Line itemSeries A Preferred Stock / AmountCommon Stock / AmountAdditional Paid–In CapitalAccumulated DeficitTotal Stockholders’ Equity
Balance at December 31, 202418,8433145,719(138,998)6,724
Conversion of preferred stock(18,843))118,84218,843
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement15,9795,980
Issuance of common stock and prefunded warrants in connection with registered direct offering122,99822,999
Issuance of common stock in connection with private placement and at-the-market program15,8045,805
Issuance costs(940)(940)
Stock-based compensation3,3993,399
Share repurchases for the payment of employee taxes(152)(152)

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is Opus Genetics's stock issued during period value registered direct offering?
Opus Genetics (IRD) reported stock issued during period value registered direct offering of $5.75M in Q4 2025.
What does stock issued during period value registered direct offering mean?
Represents the total dollar value of common stock or equity securities issued through a registered direct offering. This financing mechanism allows companies to sell securities directly to institutional investors, providing a source of capital distinct from public market offerings.

Ask your AI about Opus Genetics's stock issued during period value registered direct offering.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude